Dagmar Rosa-Bjorkeson

This profile gathers the share dealings of Dagmar Rosa-Bjorkeson across 2 companies, led by Intercept Pharmaceuticals, Inc. and Xencor Inc. Over a trading history stretching from 27 May 2021 to 27 September 2024, the count stands at 7 filings.

No open-market purchase appears, only 1 sale worth €46k. Other entries cover 5 share grants. Since January 2024: no purchases and 1 sale on the market.

The newest entry dates from 1 October 2024: an open-market sale of €46k, in Xencor Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.